355 results about "Intestinal tract diseases" patented technology

Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.

Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.

The present invention relates to methods and compositions for reducing Distress Dysfunction by restoring and maintaining homeostatic balance in the neurotransmitter systems underlying the Stress Response and the experience of distress and hedonic tone. Distress Dysfunction refers to the experience of dysfunctional emotional and physical distress that interferes with the individual's quality of life and functioning. A novel understanding of the bimodal opioid modulation of pain, and its impact, through serotonergic, dopaminergic, epinephrinergic, and norepinephrinergic processes, on hedonic tone, leads directly to new generation pharmaceutical formulations that are remarkably safe and effective for the treatment of a wide variety of Distress Dysfunctions, including anxiety, depression, anger, insomnia, mood disorders, eating disorders, sexual problems, pain, substance and behavioral addictions, gastrointestinal disorders, autistic spectrum disorders, attention-deficit and hyperactivity disorders, and other emotional and physical distress disorders. The foundation of this discovery is the power of Receptor Switchers, such as ultra-low-dose and very-low-dose opioid antagonists and GM1 ganglioside attenuators, in blocking acute and protracted excitatory opioid receptor signaling. Co-administration of Receptor Switchers with Endorphin Enhancers, such as specific cAMP PDE inhibitors and excitatory amino acids, is an excellent formulation for restoring healthy homeostatic balance to the endogenous opioid system, using the body's endorphins to reduce emotional and physical distress, and through synergistic and homeostatic processes, restoring positive hedonic tone. The addition of Synergistic Enhancers, such as amino acids, SSRI and SNRI agents, and non-opioid analgesics, as well as Exogenous Opioids, enhances and prolongs these therapeutic benefits. The novel principles discovered by this invention also teach a new generation of safe and effective formulations for the treatment of respiratory conditions, neuropathy, and nociceptive pain.

The present invention relates to a biostimulatinq agent comprising natural minerals having ion-exchanges and sorption properties, and also a biologically active vegetable stock, the natural minerals including a clinoptylolite-heulandite zeolite containing not less than 92 wt % of clinoptylolite, and/or montmorillonite clay containing not less than 92 wt % of montmorillonite, and as the biologically active vegetable stock comprises wheat bran, rye bran, oats, Japanese laminaria, madder, birch fungus, and the like.The biostimulating agent of the present invention normalizes the mineral balance of the body, produces higher therapeutical effect, for example, in using it in case of intestinal tract diseases, aterosclerosis, urinary calculosis, produces an immune-modulating and tonic effect.

The invention relates to a capsule for forcedly improving the immunity, which is a capsule formulation prepared by traditional Chinese medicines of parasites detoxifying and destroying type, heat dry dampness clearing, detoxifying and blood cooling type, cough and asthma relieving and phlegm reducing type, temperature cooling and exterior relieving type, kidney warming and yang enhancing type, health building type, resolving damp with aromatics and blood enriching type, qi invigorating type, spleen and stomach strengthening and interior warming type, invigorating blood circulation by removing blood stasis type, liver soothing and qi regulating type, yin tonifying and converging type, digestion helping type, liver clearing, vision helping and resuscitation inducing type, deswelling and pain stopping type, heart nourishing as well as fever reducing and fire purging type according to a certain preparation method. The capsule has the functions as follows: forcedly improving the immunity, clearing away heat and toxic material, detoxifying and destroying parasites, soothing the liver and regulating qi, invigorating blood circulation by removing blood stasis, building health, invigorating qi and enriching blood, regulating qi and stopping pain, inducing diuresis and excreting dampness, eliminating phlegm, relieving cough and asthma, warming kidney and enhancing yang, invigorating the spleen and stomach and the like. The capsule has effects for various headaches, dizzy and neurasthenia, and various intestinal tract diseases, abdominal pains and abdominal distension, and various waist and leg pains and various tumors, and can cure diseases when in ill, build body when not in ill, and can achieve the goal of healthy and long life if the long-term or discontinuous taking is carried out.

Using RNA samples from mononuclear blood cells, gene sequences were identified that can be used to identify patients with IBD, and then distinguish patients with Crohn's disease from those with ulcerative colitis. Sequences were identified whose overexpression was distinct to patients with IBD, Crohn's disease, and ulcerative colitis when compared to patients with non-IBD intestinal disorders. Additionally, cluster analysis was used to identify twenty-five sequences that are IBD-related, and whose transcription pattern can be used in a microarray analysis to identify patients with IBD with a sensitivity of 84% and a specificity of 100%. Cluster analysis also identified thirty-six genes that could be used to distinguish patients with Crohn's disease from those with ulcerative colitis with a sensitivity of 89% and a specificity of 80%.

The present invention relates to a compound represented by the formula

wherein ring A is a nitrogen-containing heterocycle optionally further having substituent(s), ring B is an aromatic ring optionally having substituent(s), ring C is a cyclic group optionally having substituent(s), R¹ is a hydrogen atom, a hydrocarbon group optionally having substituent(s), an acyl group, a heterocyclic group optionally having substituent(s) or an amino group optionally having substituent(s), R² is an optionally halogenated C_1-6 alkyl group, m and n are each an integer of 0 to 5, m+n is an integer of 2 to 5, and

is a single bond or a double bond, or a salt thereof and the like. Since the compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, gastrointestinal diseases, central nervous system diseases and the like.

The invention provides pharmaceutical compositions, methods for the treatment of, and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic syndromes, including hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states. In an additional aspect of the invention, compositions and methods of treatment are calibrated to the ileal brake response to surgical intervention e.g. Roux-en-Y gastric bypass (RYGB)) as both activate the ileal brake, which acts in the gastrointestinal tract and the liver of a mammal to control metabolic syndrome manifestations and thereby reverse or ameliorate the cardiovascular damage (atherosclerosis, hypertension, lipid accumulation, and the like) resulting from progression of metabolic syndrome. The net benefit is the potential to treat all of the common manifestations of metabolic syndrome, including Type 2 diabetes and obesity, with one medicament, which contains glucose as an activation agent for the ileal brake. The ileal brake is the controller for progression of metabolic syndrome, and both RYGB surgery and the oral formulation act beneficially on the metabolic syndrome manifestations via this pathway. Disclosed as well are combination medicaments that act synergistically on the ileal brake and the manifestations of metabolic syndrome.

In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to RYGB surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans.

The present invention relates to a pharmaceutical composition for treating, for example, a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) an atypical antipsychotic or a pharmaceutically acceptable salt thereof,

• • (ii) a 5-HT_1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT_1B receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally (iii) a pharmaceutically acceptable carrier.

The invention relates to a stachyose infant nourishing cereal and its preparation method. The infant nourishing cereal comprises the following raw materials: long-grain rice, millet, whole milk powder, lactalbumin powder, stachyose, cane sugar, docosahexaenoic acid, arachidonic acid, vitamin and a trace element supplement accepted by bromatology. The especially added stachyose possesses obvious proliferation effects to probiotic groups like bifidobacterium and lactic acid bacillus in human gastrointestinal tract, and is capable of promoting the synthesis of vitamin B1, vitamin B2, vitamin B6,vitamin B12 and the like as well as promoting the absorption of elements like calcium and magnesium by the gastrointestinal tract, thereby the stachyose infant nourishing cereal has the advantages ofhigh nutrition value and high physiological value. The stachyose infant nourishing cereal can effectively preventing and alleviating the infant constipation and diarrhoea, inhibiting the intestinal tract diseases, comprehensive comprehensively enhancing the infant immunization capability and raising the disease resistance of infant body.

The invention belongs to the field of health care foods and specifically relates to compound dendrobium candidum and American ginseng buccal tablets and a preparation method thereof. The method comprises the following steps of: performing ultrafine grinding on dendrobium candidum and American ginseng, taking ultrafine powder of the dendrobium candidum and the American ginseng as raw material, adding resistant starch, a sweetening agent and a bonding agent, preparing wet particles, drying, sizing, finally mixing with a lubricating agent, and then tabletting to get finished products. According to the compound dendrobium candidum and American ginseng buccal tablets prepared by the method disclosed by the invention, the raw material is subject to the ultrafine grinding, various biological active substances in the raw material can be retained to the greatest extent, the biological availability is high, and the dendrobium candidum and the American ginseng are compatible for use, so that the effects of resisting fatigue, nourishing Yin, producing body fluid and the like can be enhanced. The resistant starch is added in the buccal tablets so as to enhance the effects of preventing and treating intestinal diseases, reducing blood sugar and the like; and the compound dendrobium candidum and American ginseng buccal tablets are suitable for more people and more suitable for patients with diabetes for taking, have the characteristics of convenience in carrying, convenience in taking, easiness in control of dosage and the like, and are further in line with simple, convenient and fast consumer demands of modern people.

The invention relates to clinical application of a substituted aryl hydrazone compound and a derivative thereof serving as an anti-tumor necrosis factor inhibitor. A test result shows that the compound has a lower cytotoxicity in animal bodies, so the medical compound is expected to be used as an anti-TNF-alpha and TNF-beta inhibitor in the clinical application and is mainly used for treating some TNF related immunological diseases such as rheumatic arthritis, inflammatory bowel diseases, diabetes, hematosepsis, psoriasis, ankylosing spondylitis and some communicable diseases including HIV. A current TNF related research also shows that the medical compound can be used for treating clinical blood and solid tumor such as myelodysplastic syndrome, myelofibrosis, acute bone marrow cell leucocythemia, acute/chronic graft-versus-host reaction, ovarian cancer, nephrocyte cancer and the like.

The invention relates to a preparation comprising 5-50% by weight of Isphagula Husk; 1-20% by weight of at least one amino acid; 20-80% by weight of at least one carbohydrate and electrolytes. The preparation is for use as a therapeutical agent, such as for use in treating a state of disorder in the intestinal system of monogastric animals, including humans. A state of disorder in the intestinal system is in particular all intestinal disorders in which the epithelial layer is damaged, mostly as a result of malabsorption diarrhoea, also associated with dehydration.

The invention discloses a livestock and poultry intestinal tract regulator which comprises the following components in parts by weight: 30-60 parts of acidifying agent, 10-50 parts of prebiotics, 20-50 parts of intestinal tract endotoxin antagonist and 5-40 parts of auxiliary ingredients. The livestock and poultry intestinal tract regulator scientifically combines a plurality of functional additives, takes various etiological factors of clinical intestinal tract diseases into consideration, is wide in application range and obvious in effect, has no residues and no hidden food safety hazard compared with antibiotics, and is applicable to the function regulation of intestinal tracts of livestock and poultry; the intestinal tract functions of animals in large-scale cultivation process can be improved, and the animal feeding efficiency can be further increased. The intestinal tract regulator can be applicable to drinking water, does not add antibiotics, has no food sanitation and safety risks, and is stable in character and high in safety.

Embodiments of the invention are directed to methods of diagnosing eosinophilic gastritis (EG), or remission therefrom in a subject, wherein the methods include applying a sample from the subject to a diagnostic panel that contains selected markers for EG, analyzing the results thereof, and making a determination as to the EG status of the subject. Embodiments of the invention are also directed to methods of monitoring the pathological development or medical prognosis of EG in a subject. Embodiments of the invention are also directed to use of CDH26 as a marker for EG, eosinophilic esophagitis, or allergic inflammatory conditions. Embodiments of the invention also relate to the use of anti-CDH26-based therapeutics to treat allergic inflammatory conditions.

Bombesin receptor antagonists are provided which are compounds of formula (I) or pharmaceutically acceptable salts thereof: wherein j, k, l, m, n, q, r, Ar, Ar<1>, R<1>, R<2>, R<3>, R<4>, R<5>, R<6 >and X are as defined in the description. The compounds of the invention have an affinity for the BB1 receptor and some of them also have affinity for the BB2 receptor. Accordingly they may be useful for the diagnosis, prevention, or treatment of male and female sexual dysfunction. They can also be used in the diagnosis, prevention or treatment of anxiety and panic disorders, social phobia, depression, psychoses, sleeping disorders, memory impairment, pulmonary hypertension, lung repair and lung development disorders, cancer including prostate cancer and pancreatic cancer, hepatic porphyria, gastrointestinal secretory disturbances, gastrointestinal disorders including colitis, Crohn's disease and inflammatory bowel disease, emesis, anorexia, pain, seasonal affective disorders, feeding disorders or pruritus.

The invention belongs to the technical field of the food beverage, which particular relates to a black tea fungus beverage as well as a preparation technology and application thereof. The tea fungus beverage consists of the following raw materials in parts by weight: 1000 parts of water, 100-300 parts of black tea fungus bacteria liquid, 1-10 parts of red date, 1-5 parts of longan, 1-5 parts of hawthorn, 0-5 parts of dried lichee, 2-10 parts of black tea, 0-5 parts of sea-buckthorn and 50-200 parts of sweetening agent. The black tea fungus beverage has the health-care functions such as appetizing, invigorating stomach, aiding digestion and increasing appetite, has a good promoting function on intestinal tract diseases, has the advantages of varied tastes and abundant nutrition ingredients, is suitable for both young and old and can be directly drunk by people. According to the preparation technology of the product, the black tea fungus bacteria liquid is used for preparing, and various raw materials are mixed and heated after being pre-processed and are sterilized and disinfected after being filled. The preparation technology is simple to operate, is safe and clean to operate, andis suitable for industrial production, and the production cost is lowered. The product has the functions of eliminating fat, resisting oxidation, enhancing resistance, maintaining beauty and keep young and the like.

The invention discloses a fermented traditional Chinese medicine for treating the reduction of the egg production of laying hens. The fermented traditional Chinese medicine is prepared from the following traditional Chinese medicine raw materials in parts by weight by fermentation by virtue of zymophyte: 1-15 parts of acanthopanax, 1-15 parts of common curculigo rhizome, 1-15 parts of polygonum multiflorum, 1-15 parts of Chinese angelica, 1-15 of folium artemisiae argyi, 5-20 parts of dangshen, 5-20 parts of bighead atractylodes rhizome, 1-10 parts of hawthorn, 1-10 parts of medicated leaven, 1-10 parts of malt and 1-10 parts of pine needles. Meanwhile, the invention discloses a preparation method of the fermented traditional Chinese medicine. The preparation method comprises the following steps: mixing and crushing the traditional Chinese medicine raw materials, screening with a 50-80 mesh sieve, carrying out high-temperature sterilization, adding water and zymophyte, and then putting in a fermentation tank for fermentation so as to obtain the product; and drying, sieving and subpackaging the product. The fermented traditional Chinese medicine prepared by the method has the advantages that the content of effective components and active materials is high so that the fermented traditional Chinese medicine can be efficiently absorbed by animals; and the zymophyte for fermentation is beneficial to the maintenance of intestinal tract environments of livestock and poultry and the prevention and treatment of secondary infection and other intestinal diseases.